Posted: January 25, 2021
Authors: Jian Hang Lam, Amit Kumar Khan, Thomas Andrew Cornell, Regine Josefine Dress, Teck Wan Chia, Wen Wang William Yeow, Nur Khairiah Mohd-Ismail, Shrinivas Venkatraman, Kim Tien Ng, Yee-Joo Tan, Danielle E. Anderson, Florent Ginhoux, Madhavan Nallani
Multiple successful vaccines against SARS-CoV-2 are urgently needed to address the ongoing Covid-19 pandemic. In the present work, we describe a subunit vaccine based on the SARS-CoV-2 spike protein co-administered with CpG adjuvant. To enhance the immunogenicity of our formulation, both antigen and adjuvant were encapsulated with our proprietary artificial cell membrane (ACM) polymersome technology. Structurally, ACM polymersomes are self-assembling nanoscale vesicles made up of an amphiphilic block copolymer comprising of polybutadiene-b-polyethylene glycol and a cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane. Functionally, ACM polymersomes serve as delivery vehicles that are efficiently taken up by dendritic cells, which are key initiators of the adaptive immune response. Two doses of our formulation elicit robust neutralizing titers in C57BL/6 mice that persist at least 40 days. Furthermore, we confirm the presence of memory CD4+ and CD8+ T cells that produce Th1 cytokines. This study is an important step towards the development of an efficacious vaccine in humans.
The authors declare the following competing financial interests: D.E.A. and Y.J.T. developed the cPass kit; J.H.L, A.K.K., T.A.C., T.W.C., W.W.W.Y., and M.N. are employees of ACM Biolabs Pte Ltd; F.G. is part of the ACM SAB. The authors declare no non-financial competing interests.